Adocia Targeting Insulin Combos After Ultra-Fast Insulin Deal With Lilly

A concentrated insulin formulation and extra clinical data were instrumental in Lilly’s second deal on the use of Adocia’s BioChaperone technology for an ultra-fast-acting insulin, with the latest agreement between the two companies providing funds for Adocia to pursue other insulin research areas.

More from Platform Technologies

More from Advanced Technologies